Download the webinar slides. The specialty pharmacy industry has dramatically changed over the past few years and is now one of the fastest growing sources of revenue in the prescription drug marketplace. As a result, payers and PBMs... Read More
Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Private Equity Investing in Specialty Pharmacy & Pharmaceutical Companies

The impact of Direct and Indirect Remuneration ("DIR") fees on the specialty pharmacy industry cannot be overstated and has been widely reported in White Papers and industry news reports. However, the impact of DIR fees on the 340B sector is only... Read More
Blogs & Articles | Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Section 340B In-House and Contract Pharmacies

In this White Paper, the National Association of Specialty Pharmacy (NASP) and Frier Levitt explore the disparate impact that certain Pharmacy Benefit Managers (PBMs) "Direct and Indirect Remuneration" fees (commonly known as "DIR Fees") have on... Read More
Defending Pharmacies in PBM Audits | Pharmacy Law | Webinars

A White Paper by Frier Levitt examines the ongoing practice by Pharmacy Benefit Managers (PBMs) to increase corporate profits through murky "Direct and Indirect Remuneration" fees—commonly known as "DIR Fees"—charged to community oncology... Read More
Blogs & Articles | Defending Pharmacies in PBM Audits | DIR Fees | Pharmacy Law | Physician Dispensing

Pharmacy Benefit Managers (PBMs) own their own Specialty Pharmacies (SPs) and convince Plan Sponsors to allow the PBMs to become the exclusive provider of expensive specialty drugs.  PBMs have recently enjoyed significant revenue expansion and... Read More
Defending Pharmacies in PBM Audits | Medicare, Medicaid, and Other Commercial Payor Audits & Appeals | Payor Network Access and Defense of Network Terminations | Pharmacy Law